Skip to content
Academic Highlights
J Clin Psychiatry
November 2025
Real-World Implementation of Xanomeline-Trospium in Schizophrenia: A Consensus Panel Report
Full Article
Read the complete peer-reviewed article in J Clin Psychiatry.
Clinical Summary
Patients with schizophrenia often need lifelong treatment, yet standard dopamine-blocking antipsychotics leave many with persistent negative or cognitive symptoms and accumulate burdens such as EPS, metabolic effects, and prolactin elevation. This report addresses how clinicians can actually start, titrate, and combine xanomeline-trospium in practice while managing the early gastrointestinal and anticholinergic issues that most affect adherence.
FAQ
What makes xanomeline-trospium different from standard antipsychotics for schizophrenia?
12 questions
Key Takeaways
In the pooled 5-week EMERGENT 1–3 trials, XT separated from placebo on PANSS total and positive subscale scores at the first assessment, while PANSS negative symptom benefits did not reach statistical significance until week 3; this timing can help set expectations for early follow-up.
6 takeaways · 5 clinical pearls
Clinical Guide
How should clinicians initiate xanomeline-trospium for hospitalized patients with schizophrenia?
5 steps
Clinical Guide
How should clinicians switch or add xanomeline-trospium when a patient with schizophrenia is already taking an antipsychotic?
6 steps
Clinical Guide
How should clinicians initiate and titrate xanomeline-trospium for outpatients with schizophrenia?
6 steps
PDF
Download